Fool Article Touts Undervaluation, But DeepValue Report Exposes High Risks and Insider Selling

What happened

A Motley Fool article published on April 2, 2026, argues Palantir may be undervalued based on an unspecified metric, claiming not all numbers indicate it's expensive. However, the DeepValue master report, drawing from recent SEC filings, reveals Palantir trades at a P/E of 202 and EV/EBITDA of 218, offering no margin of safety even with strong growth. Critical filings detail that many contracts include termination-for-convenience clauses and unguaranteed options, making leading indicators like remaining deal value (RDV) and total contract value (TCV) unreliable for forward revenue. Insider activity shows heavy selling by multiple senior executives and director Peter Thiel in early 2026, suggesting potential concerns about near-term prospects amid high valuation. The report maintains a WAIT rating, advising investors to wait for a cheaper entry near $110 or clearer evidence of sustained U.S. commercial RDV growth and funded government execution.

Implication

The Fool article's optimistic take is contradicted by detailed SEC filings that highlight Palantir's extreme valuation multiples and lack of margin of safety, making the stock vulnerable to multiple compression. Insider selling patterns, including clustered sales by key executives, signal potential skepticism about sustainability at current levels, warranting heightened scrutiny. Palantir's growth narrative relies on bootcamp conversions and government task orders, but filings warn of seasonality and option non-exercise that could derail revenue forecasts. Upcoming Q1 2026 results must confirm guidance and RDV trends without attributing variances to contractual weaknesses to avoid a bearish repricing. Investors are better off waiting for a pullback to the $110 attractive entry point or demonstrable improvement in funded backlog visibility before considering a position.

Thesis delta

The new article does not shift the investment thesis; Palantir remains a WAIT-rated stock due to its high valuation, fragile growth assumptions from optioned contracts, and insider selling red flags. Investors should not be swayed by vague undervaluation metrics and instead focus on concrete risks outlined in filings, such as RDV sensitivity and government funding uncertainty. Any material change would require evidence of sustained U.S. commercial RDV growth above 80% Y/Y and no guidance misses attributed to seasonality or termination clauses.